{"doi":"10.21873/anticanres.14216","title":"Noncalcemic Vitamin D Hydroxyderivatives Inhibit Human Oral Squamous Cell Carcinoma and Down-regulate Hedgehog and WNT/β-Catenin Pathways","abstract":"Background/Aim: The hormonally-active form of vitamin D, 1,25(OH) 2 D 3 , demonstrated activity against oral squamous cell carcinoma (OSCC). Cytochrome P450scc (CYP11A1)-derived vitamin D hydroxyderivatives, such as 20(OH)D 3 and 1,20(OH) 2 D 3 , have overlapping beneficial effects with 1,25(OH) 2 D 3 without causing hypercalcemia. This study sought to determine (i) whether 20(OH)D 3 and 1,20(OH) 2 D 3 exhibit antitumor effects against OSCC comparable to those of 1,25(OH) 2 D 3 and (ii) whether these effects may stem from down-regulation of sonic hedgehog (SHH) or WNT/-catenin signaling pathways. Materials and Methods: Effects on CAL-27 cells were assessed by 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium inner salt and spheroid assays. Signaling pathways were assessed by immunofluorescence and western blotting. Results: 20(OH)D 3 and 1,20(OH) 2 D 3 inhibited the growth of CAL-27 and demonstrated inhibition of WNT/-catenin and the SHH signaling as evidenced by down-regulation of nuclear translocation of glioma-associated oncogene 1(GLI1) and -catenin. Conclusion: Noncalcemic vitamin D hydroxyderivatives demonstrated antitumor activities against OSCC comparable to those of 1,25(OH) 2 D 3 . Their activities against SHH and the WNT/-catenin pathways provide insight for a possible target for OSCC treatment.","journal":"Anticancer Research","year":2020,"id":75977,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9591,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":396807,"name":"Georgeta Bocheva","orcid":"0000-0002-3532-7009","position":1,"is_corresponding":false},{"id":259109,"name":"Tae‐Kang Kim","orcid":"0000-0003-1394-4134","position":2,"is_corresponding":false},{"id":94308,"name":"Anna A. Brożyna","orcid":"0000-0002-3195-9965","position":3,"is_corresponding":false},{"id":259108,"name":"Zorica Janjetović","orcid":"0000-0001-6108-2212","position":4,"is_corresponding":false},{"id":315214,"name":"Mohammad Athar","orcid":"0000-0002-4728-2530","position":5,"is_corresponding":false},{"id":257554,"name":"Robert C. Tuckey","orcid":"0000-0002-5022-4729","position":6,"is_corresponding":false},{"id":97237,"name":"Andrzej Słomiński","orcid":"0000-0001-8963-3995","position":7,"is_corresponding":false},{"id":298817,"name":"Allen S. W. Oak","orcid":"0000-0003-2837-6846","position":0,"is_corresponding":true}],"reference_count":39,"raw_metadata":null,"created_at":"2026-07-18T21:47:46.469293Z","pmid":"32366390","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}